Literature DB >> 31715278

Nanomedicine - advantages for their use in rheumatoid arthritis theranostics.

Shuyi Xiao1, Yufu Tang2, Zhuang Lv3, Yimu Lin4, Liang Chen5.   

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease accompanies with synovial inflammation and progressive bone destruction. Currently, anti-rheumatic drugs need high dose and frequent use for a long-term, which lead to serious side effect and low patient compliance. To overcome above problems and improve clinical efficacy, nano-technology with targeting ability, sustained release and so forth, has been proposed on RA treatment and already achieved success in RA animal models. In this review, authors summarize and illustrate representative nanomedicine targeting to RA states, which is achieved either through passive or active targeting with high affinity to the receptors that are over-expressed in macrophages or angiogenesis. In particular, authors highlight the new strategies to promote the efficacy of nanoscale treatments through phototherapy and the addition of contrast elements for theranostic application. The described advances may pave the way to better understanding and designing the novel nanomedicine and multifunctional nano-system on efficient RA treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Nanomedicine; Phototherapy; Rheumatoid arthritis; Target delivery; Theranostic

Year:  2019        PMID: 31715278     DOI: 10.1016/j.jconrel.2019.11.008

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

Review 1.  Proper animal experimental designs for preclinical research of biomaterials for intervertebral disc regeneration.

Authors:  Yizhong Peng; Xiangcheng Qing; Hongyang Shu; Shuo Tian; Wenbo Yang; Songfeng Chen; Hui Lin; Xiao Lv; Lei Zhao; Xi Chen; Feifei Pu; Donghua Huang; Xu Cao; Zengwu Shao
Journal:  Biomater Transl       Date:  2021-06-28

2.  Polymer Nanomedicines with Ph-Sensitive Release of Dexamethasone for the Localized Treatment of Inflammation.

Authors:  Alena Libánská; Eva Randárová; Franck Lager; Gilles Renault; Daniel Scherman; Tomáš Etrych
Journal:  Pharmaceutics       Date:  2020-07-25       Impact factor: 6.321

3.  In Vivo Fluorescence Imaging of Passive Inflammation Site Accumulation of Liposomes via Intravenous Administration Focused on Their Surface Charge and PEG Modification.

Authors:  Hisako Ibaraki; Akihiro Takeda; Naoki Arima; Naruhiro Hatakeyama; Yuuki Takashima; Yasuo Seta; Takanori Kanazawa
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

Review 4.  Instructive cartilage regeneration modalities with advanced therapeutic implantations under abnormal conditions.

Authors:  Zhonghan Wang; Hanxiang Le; Yanbing Wang; He Liu; Zuhao Li; Xiaoyu Yang; Chenyu Wang; Jianxun Ding; Xuesi Chen
Journal:  Bioact Mater       Date:  2021-11-18

Review 5.  Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment.

Authors:  Simran Nasra; Dhiraj Bhatia; Ashutosh Kumar
Journal:  Nanoscale Adv       Date:  2022-07-26

Review 6.  Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.

Authors:  Qin Wang; Xianyan Qin; Jiyu Fang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2021-03-12       Impact factor: 11.413

Review 7.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

Review 8.  Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment.

Authors:  Shuang Li; Jin Su; Wei Cai; Jian-Xin Liu
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

9.  Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis.

Authors:  Caiwei Yu; Hui Liu; Chunjing Guo; Qiang Chen; Yanguo Su; Huimin Guo; Xiaoya Hou; Feng Zhao; Huaying Fan; Hui Xu; Yan Zhao; Xiaofeng Mu; Guohua Wang; Haiyu Xu; Daquan Chen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.